The effectiveness of dapagliflozin and lixisenatide in managing Type 2 diabetes: a real-world observational study

被引：0
|
作者：
Duffy, A. [1 ]
Smith, C. [1 ]
Harrow, C. [1 ]
McGowan, N. [1 ]
McIntyre, M. [1 ]
So, B. [1 ]
Jones, C. [2 ]
Gonzalez, N. [1 ]
机构：
[1] Royal Alexandra Hosp, Dept Endocrinol, Paisley, Renfrew, Scotland
[2] Inverclyde Royal Hosp, Dept Endocrinol, Greenock, Scotland
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P437
引用
收藏
页码：166 / 166
页数：1
相关论文
共 50 条
  • [1] Effectiveness of Dapagliflozin in Treating Type 2 Diabetes Mellitus in a Real-World Indian Setting
    Jadhav, Uday M.
    Chawla, Manoj
    Rai, Sandeep
    Manjula, S.
    Kumar, M. Krishna
    JOURNAL OF DIABETOLOGY, 2025, 16 (02) : 176 - 181
  • [2] Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study
    Grunberger, George
    Rosenfeld, Cheryl R.
    Bode, Bruce W.
    Abbott, Scott D.
    Nikkel, Carla
    Shi, Leon
    Strange, Poul
    DRUGS-REAL WORLD OUTCOMES, 2020, 7 (01) : 31 - 40
  • [3] Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study
    George Grunberger
    Cheryl R. Rosenfeld
    Bruce W. Bode
    Scott D. Abbott
    Carla Nikkel
    Leon Shi
    Poul Strange
    Drugs - Real World Outcomes, 2020, 7 : 31 - 40
  • [4] Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States
    Blonde, Lawrence
    Patel, Charmi
    Wu, Bingcao
    Chen, Yen-Wen
    Pericone, Christopher D.
    Bookhart, Brahim
    ADVANCES IN THERAPY, 2021, 38 (01) : 594 - 606
  • [5] Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States
    Lawrence Blonde
    Charmi Patel
    Bingcao Wu
    Yen-Wen Chen
    Christopher D. Pericone
    Brahim Bookhart
    Advances in Therapy, 2021, 38 : 594 - 606
  • [6] The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
    McGurnaghan, Stuart J.
    Brierley, Liam
    Caparrotta, Thomas M.
    McKeigue, Paul M.
    Blackbourn, Luke A. K.
    Wild, Sarah H.
    Leese, Graham P.
    McCrimmon, Rory J.
    McKnight, John A.
    Pearson, Ewan R.
    Petrie, John R.
    Sattar, Naveed
    Colhoun, Helen M.
    DIABETOLOGIA, 2019, 62 (04) : 621 - 632
  • [7] The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
    Stuart J. McGurnaghan
    Liam Brierley
    Thomas M. Caparrotta
    Paul M. McKeigue
    Luke A. K. Blackbourn
    Sarah H. Wild
    Graham P. Leese
    Rory J. McCrimmon
    John A. McKnight
    Ewan R. Pearson
    John R. Petrie
    Naveed Sattar
    Helen M. Colhoun
    Diabetologia, 2019, 62 : 621 - 632
  • [8] Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population
    Samajdar, Shambo Samrat
    Mukherjee, Shatavisa
    Gokalani, Rutul
    Bhattacharyya, Supratik
    Saboo, Banshi
    Joshi, Shashank
    CLINICAL DIABETOLOGY, 2024,
  • [9] Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study
    Malik, Rayaz A.
    Hwu, Chii-Min
    Jammah, Anwar A.
    Arteaga-Diaz, Juan M.
    Djaballah, Khier
    Pilorget, Valerie
    Alvarez, Agustina
    Vera, Carine
    Vikulova, Olga
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2811 - 2819
  • [10] Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study
    Riccardo Candido
    Monica Modugno
    Monica Larosa
    Maria Chiara Rossi
    Antonio Nicolucci
    Enrico Gabellieri
    Diabetes Therapy, 2023, 14 : 77 - 92
12345